Fig. 4.
Fig. 4. Platelet counts in C57BL/10 mice. / Mice were treated with 1 μg mIL-6 (▴) or PBS–0.5% BSA (■) every 12 hours for 6 consecutive days. Additionally, mice were injected with 500 μg rabbit anti-TPO pAb (open symbols) or irrelevant control rabbit IgG (filled symbols, dashed line). Venous blood was drawn on day 1 (pretreatment) and every second day thereafter and was analyzed for platelet counts. Data are expressed as mean ± SEM for n = 3 per group. The increase in platelet counts in mIL-6–treated animals was significant (P < .05), as were the differences between mIL-6 and mIL-6 plus anti-TPO pAb-treated mice (P < .05).

Platelet counts in C57BL/10 mice.

Mice were treated with 1 μg mIL-6 (▴) or PBS–0.5% BSA (■) every 12 hours for 6 consecutive days. Additionally, mice were injected with 500 μg rabbit anti-TPO pAb (open symbols) or irrelevant control rabbit IgG (filled symbols, dashed line). Venous blood was drawn on day 1 (pretreatment) and every second day thereafter and was analyzed for platelet counts. Data are expressed as mean ± SEM for n = 3 per group. The increase in platelet counts in mIL-6–treated animals was significant (P < .05), as were the differences between mIL-6 and mIL-6 plus anti-TPO pAb-treated mice (P < .05).

Close Modal

or Create an Account

Close Modal
Close Modal